Celldex Therapeutics (CLDX) Competitors

$32.28 -1.69 (-4.97%)

Closing price 04:00 PM Eastern

Extended Trading

$32.30 +0.02 (+0.05%)

As of 04:10 PM Eastern

CLDX vs. HALO, RGEN, ALKS, LGND, and FOLD

Should you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Halozyme Therapeutics (HALO), Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), and Amicus Therapeutics (FOLD). These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Halozyme Therapeutics has a net margin of 22.69% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 136.12% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	22.69%	136.12%	20.69%
Celldex Therapeutics	N/A	-50.72%	-46.59%

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Halozyme Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.63	$316.89M	$2.49	26.67
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A

Halozyme Therapeutics presently has a consensus target price of $79.11, suggesting a potential upside of 19.13%. Celldex Therapeutics has a consensus target price of $48.00, suggesting a potential upside of 48.70%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.42
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Halozyme Therapeutics had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 17 mentions for Halozyme Therapeutics and 10 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.60 beat Celldex Therapeutics' score of 0.10 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Repligen?

Repligen (NASDAQ:RGEN) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	8.85	$48.89M	$0.90	128.68
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A

97.6% of Repligen shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Repligen currently has a consensus target price of $169.62, suggesting a potential upside of 46.46%. Celldex Therapeutics has a consensus target price of $48.00, suggesting a potential upside of 48.70%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Repligen has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

In the previous week, Repligen had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 19 mentions for Repligen and 10 mentions for Celldex Therapeutics. Repligen's average media sentiment score of 0.40 beat Celldex Therapeutics' score of 0.10 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Repligen has a net margin of 6.73% compared to Celldex Therapeutics' net margin of 0.00%. Repligen's return on equity of 4.88% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Repligen beats Celldex Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Alkermes currently has a consensus target price of $45.21, suggesting a potential upside of 27.47%. Celldex Therapeutics has a consensus target price of $48.00, suggesting a potential upside of 48.70%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.82
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.01	$241.66M	$0.90	39.41
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A

Alkermes has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

In the previous week, Alkermes had 14 more articles in the media than Celldex Therapeutics. MarketBeat recorded 24 mentions for Alkermes and 10 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 0.65 beat Celldex Therapeutics' score of 0.10 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alkermes has a net margin of 9.78% compared to Celldex Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Alkermes beats Celldex Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Celldex Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Celldex Therapeutics currently has a consensus target price of $48.00, suggesting a potential upside of 48.70%. Ligand Pharmaceuticals has a consensus target price of $257.71, suggesting a potential upside of 16.89%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Ligand Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A
Ligand Pharmaceuticals	$268.09M	16.48	$124.45M	$7.37	29.92

In the previous week, Ligand Pharmaceuticals had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 21 mentions for Ligand Pharmaceuticals and 10 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.10 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats Celldex Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Amicus Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Celldex Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Celldex Therapeutics has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -4.27%. Amicus Therapeutics' return on equity of 4.15% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Amicus Therapeutics	-4.27%	4.15%	1.09%

Amicus Therapeutics has higher revenue and earnings than Celldex Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,645.23	-$258.76M	-$4.26	N/A
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Celldex Therapeutics currently has a consensus price target of $48.00, suggesting a potential upside of 48.70%. Amicus Therapeutics has a consensus price target of $14.56, suggesting a potential upside of 0.50%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Celldex Therapeutics had 9 more articles in the media than Amicus Therapeutics. MarketBeat recorded 10 mentions for Celldex Therapeutics and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat Celldex Therapeutics' score of 0.10 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Amicus Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.53B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-7.58	15.19	20.66	25.70
Price / Sales	1,645.23	194.53	527.64	64.90
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	4.07	6.94	9.77	6.74
Net Income	-$258.76M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	0.12%	4.63%	6.28%	8.98%
1 Year Performance	76.10%	78.21%	41.81%	42.45%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.6095 of 5 stars	$32.28 -5.0%	$48.00 +48.7%	+85.3%	$2.53B	$1.54M	N/A	150	Earnings Report Analyst Forecast
HALO Halozyme Therapeutics	4.0662 of 5 stars	$64.49 -1.3%	$78.56 +21.8%	-2.6%	$7.74B	$1.40B	25.90	390
RGEN Repligen	3.5506 of 5 stars	$118.29 +0.6%	$170.93 +44.5%	+0.2%	$6.63B	$738.26M	139.16	2,000	Earnings Report
ALKS Alkermes	3.2758 of 5 stars	$33.68 +1.1%	$44.07 +30.8%	+16.1%	$5.54B	$1.48B	23.55	2,050
LGND Ligand Pharmaceuticals	3.6248 of 5 stars	$241.79 +4.5%	$247.29 +2.3%	+111.9%	$4.63B	$268.09M	41.47	80	Earnings Report Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, RGEN, ALKS, LGND, and FOLD

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

How does Celldex Therapeutics compare to Repligen?

Summary

How does Celldex Therapeutics compare to Alkermes?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to Amicus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, RGEN, ALKS, LGND, and FOLD

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Is HALO or CLDX more profitable?

Do insiders & institutionals have more ownership in HALO or CLDX?

Which has more risk and volatility, HALO or CLDX?

Which has preferable earnings & valuation, HALO or CLDX?

Do analysts prefer HALO or CLDX?

Does the media prefer HALO or CLDX?

Summary

How does Celldex Therapeutics compare to Repligen?

Which has preferable valuation & earnings, RGEN or CLDX?

Do institutionals and insiders hold more shares of RGEN or CLDX?

Do analysts prefer RGEN or CLDX?

Which has more risk & volatility, RGEN or CLDX?

Does the media refer more to RGEN or CLDX?

Is RGEN or CLDX more profitable?

Summary

How does Celldex Therapeutics compare to Alkermes?

Do analysts prefer ALKS or CLDX?

Which has better valuation and earnings, ALKS or CLDX?

Which has more risk and volatility, ALKS or CLDX?

Does the media refer more to ALKS or CLDX?

Do institutionals and insiders hold more shares of ALKS or CLDX?

Is ALKS or CLDX more profitable?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Is CLDX or LGND more profitable?

Do institutionals & insiders hold more shares of CLDX or LGND?

Which has more risk and volatility, CLDX or LGND?

Do analysts recommend CLDX or LGND?

Which has better earnings and valuation, CLDX or LGND?

Does the media refer more to CLDX or LGND?

Summary

How does Celldex Therapeutics compare to Amicus Therapeutics?

Which has more risk and volatility, CLDX or FOLD?

Is CLDX or FOLD more profitable?

Which has preferable earnings & valuation, CLDX or FOLD?

Do analysts recommend CLDX or FOLD?

Does the media favor CLDX or FOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools